To further specify the cellular origin and nature of anaplastic large-cell lymphoma (ALCL) and its relationship t o other lymphoid neoplasms, particularly Hodgkin's disease IHD), we investigated the presence of cytotoxic molecules in a large well-characterized series of these tumors. For expression of the cytotoxic molecules perforin and granzyme B, in situ hybridization (ISH) and immunohistology were used, respectively. Overall, 23 of 25 ALCLs of T/null phenotype and five (three mixed cellularity and two nodular sclerosis) of 57 HD cases showed the presence of perforin transcripts and/or granzyme B molecules in neoplastic cells. Polymerase chain reaction (PCR) analysis of ALCLs showed that most (10 of 11) cases of null-cell ALCL (null-ALCL) contained a clonal rearrangement of T-cell receptor &chain genes, as did NAPLASTIC LARGE-CELL lymphoma (ALCL) has re-
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The tumor cells tend to grow in cohesive sheets, home around lymphoid follicles, and spread within sinuses.'-3 The majority of ALCL cases carry T-cell antigens on the neoplastic cells (T-ALCL), whereas other cases either express B-cell antigens (B-ALCL) or lack both T-cell and B-cell antigens (null-ALCL). Among T-and null-ALCLs, a primary systemic subentity with lymphonodal and/or extranodal manifestations characterized by rapid progression and a primary cutaneous subentity with exclusive skin involvement and a favorable disease course have been di~tinguished.~-* Although the lymphoid origin of the various forms of ALCL is certain, their precise normal cellular counterparts and their relationship to each other is far from clear.' Furthermore, the borderline between ALCL and Hodgkin's disease (HD) has not been clarified which is indicated by the identification of CD30+ neoplasms displaying features of both ALCL and HD (ALCL Hodgkin's-like). ' Perforin and granzyme B are two well-characterized cytotoxic molecules that play an important role in one major pathway leading to apoptosis.'-'' Perforin facilitates the entry of granzyme molecules into target cells, and these molecules then activate the apoptotic protease CPP32.I' The genes for both perforinI3 and granzymes14 have been cloned, and antibodies directed against these molecules have been generated. These proved to be suitable for a selective detection of these antigens. 15 The presence of granzyme B has been found to be largely restricted to activated cytotoxic T cells and natural killer c e l l~. ' '~~~~~~ Similarly, perforin expression appears to occur almost exclusively in cytotoxic cells.' Therefore, analysis of the expression of these antigens in lymphomas in conjunction with other marker molecules can further specify the cellular origin of these malignancies. Taking advantage of these possibilities, we investigated 37 cases of ALCL, 57 cases of HD, and some non-ALCL peripheral T-cell lympho-T-cell ALCL (T-ALCL; 9 of 10 cases). However, both cytotoxic molecules and clonally rearranged T-cell receptor 8-chain genes were absent in seven of seven and eight of nine cases of B-cell ALCL (B-ALCL), respectively. These data show that all or nearly all T-ALCLs, irrespective of the clinical subform or the lack of T-cell-associated molecules, are derived from activated cytotoxic T cells. The same appears t o be true for the neoplastic cells of rare HD cases. These findings indicate that T-ALCLs are different from B-ALCLs and the majority of HD cases, and suggest that some HD cases, especially those with T-cell antigen-positive tumor cells, may be closely related t o T-ALCL, at least in terms of cellular origin. 0 1996 by The American Society of Hematology.
mas for the presence of the above-mentioned molecules. The data obtained indicate that most T-ALCLs, independent of the immunophenotypic or clinical subform, and rare cases of HD are derived from cytotoxic T cells. Immunohistology. Four-micrometer sections of paraffin-embedded tissue blocks were stained using the immunoalkaline phosphatase (APAAP) method." The primary monoclonal antibodies were Ber-H2 (CD30), L26 (CD20), PFl (T-cell antigen receptor P-chain), PGM-1 and KP-1 (CD68), C3D1 (CD15), and E29 (epithelial membrane antigen). For CD3 detection, a polyclonal antibody was used. EBV-encoded latent membrane protein 1 was detected with a cocktail of four antibodies (Csl to 0 4 ) . With the exception of PFl (TCell Sciences, Cambridge, MA) and a monoclonal anti-CD8 antibody (C8-144, a gift from Dr D. Mason, Oxford, UK), all antibodies were purchased from DAKO (GlOStNp, Denmark). A monoclonal antibody specific for CD56 (123C3) was from Monosan (Uden, The Netherlands). The antibody against granzyme B (GrB7"; kindly provided by Dr J.A. Kummer, Amsterdam, The Netherlands) was used in a concentration of 1500. All antibodies except PFI, which required proteolytic digestion, were applied after a high-pressure cooking pretreatment for antigen retrieval in a 10 mmom citrate buffer, pH 6.0. For detection of granzyme B, the biotin-streptavidin method was used.
MATERIALS AND METHODS

Materials
The cRNA probe was prepared by subcloning a perforin gene cDNA fragment (929 bpI3; kindly provided by Dr M.G. Lichtenheld, Department of Microbiology and Immunology, University of Miami, Miami, FL) in the run-off transcription vector pGEMl (Promega Biotec, Heidelberg, Germany). This probe contains exon 2 and exon 3 sequences. The nucleic acid sequence of the probe was determined on DNA sequencer model 373 (Applied Biosystems, Foster City, CA) and proved to conform to published data." The EBER (EBV-encoded small nuclear transcripts) probe was kindly donated by Dr. G. Niedobitek (Birmingham, UK).
After linearization, 3SS-labeled run-off antisense and sense (control) transcripts were generated using T7 or SP6 RNA polymerases (Promega-Biotech, Madison, WI). In situ hybridization (ISH) for the detection of perforin transcripts was performed as described previously." In brief, dewaxed and rehydrated paraffin sections were exposed to 0.2N HCl and 0.125 mg/mL pronase (Boehringer Mannheim, Mannheim, Germany), followed by acetylation with 0.1 mom triethanolamine, pH 8.0/0.25% (voVvol) acetic anhydride and dehydration through graded ethanols. Slides were hybridized to 2 to 4 X 10' cpm of labeled probes ovemight at 50°C. Washing and autoradiography were performed as previously described." Double-labeling with sequential immunohistology (for CD30) and ISH (for perforin transcripts) was performed as reported previously." Simultaneous labeling for perforin transcripts and EBER molecules was performed as described.2') Polymerase chain reaction analysis of T-cell receptor P gene rearrangement. Total genomic DNA from null-, T-, and B-ALCL was prepared from 20-pm thick paraffin sections using an automated DNA extractor (AB1 341A; Applied Biosystems, Weiterstadt, Germany) according to the supplier's recommendations, and the concentration of the DNA was determined photometrically. For the detection of T-cell receptor 0 gene rearrangements, an aliquot of 500 ng DNA was subjected to a seminested polymerase chain reaction (PCR). The first round consisted of 40 cycles of amplification (92°C for 1 minute, 55°C for 40 seconds, and 72°C for 30 seconds) using a VP consensus prime?' (400 ng) in conjunction with two J p consen- In situ hybridization.
UITma-DNA-polymerase (2.5 U; Perkin-Elmer) was kept constant in both PCR assays.' The analysis of the PCR products was performed with an automated DNA sequencer (AB1 373A; Applied Biosystems) using the GeneScan software, allowing a very sensitive detection of PCR products that differ by only one base in length.
RESULTS
T-and null-ALCL. Perforin-specific transcripts were detectable in almost all tumor cells of 22 of 25 cases of ALCL with T/null phenotype ( Fig 1A and Table 1) , whereas ISH experiments with the sense (control) probe showed only weak background signal homogenously distributed over the tissue (not shown). The signal intensity was considerably stronger compared with the level in reactive cells containing perforin transcripts, and the signals were clearly visible after an exposure time of 2 weeks. Allocation of the perforinspecific signals to tumor cells was confirmed in 10 cases by sequential immunohistology for CD30 and by ISH for perforin transcripts (Fig 1B) .
Immunohistologic reactivity specific for granzyme B was found in 19 of 21 cases (Fig IC and Table 1 ). In contradistinction to the expression of perforin transcripts, the number of labeled cells varied considerably from case to case. In a few cases, only sparse but clearly neoplastic cells contained granzyme B, but most cases displayed many labeled tumor cells (20% to >80%). Additional phenotypic analysis for Tcell antigens ( Table 1) showed expression of CD8 in nine of 21 cases and CD4 in two of four cases (cases with frozen material available). CD56 was found in variable numbers of reactive cells but not in neoplastic cells in 13 of 13 cases (Table 1) . PCR analysis of 21 T-or null-ALCL cases, in part overlapping with the cases investigated for cytotoxic molecules, showed clonally rearranged T-cell receptor pchain gene in nine of 10 cases of T-ALCL and 10 of 11 cases of null-ALCL (Fig 2) .
Perforin-specific signals and granzyme B were not detected in the neoplastic cells of these lymphomas (Table l). However, variable quantities of small reactive lymphoid cells clearly contained perforin transcripts in all cases, demonstrating that the absence of labeling of neoplastic cells was not due to artifactual loss of RNA during tissue processing or ISH experiments. Similarly, expression of granzyme B was restricted to nonneoplastic cells in these tissues (Fig 1D) . Rearrangement of the T-cell receptor 0-chain gene as investigated by PCR was found in one of nine cases from this group.
Among five cases investigated, expression of perforin transcripts was restricted to reactive cells in all cases, whereas expression of granzyme B was found in the tumor cells from one of three cases ( Table 2) .
A total of 49 unselected cases of classic HD and eight cases subsequently selected because of the presence of T-cell antigen-positive neoplastic cells were investigated. ISH showed expression of perforin transcripts in neoplastic cells in four cases and labeling of reactive cells in all cases (Fig 1E and Tables 2 and 3 ). Additional doublelabeling for EBER and perforin performed in 10 EBV-associated HD cases confirmed the allocation of signals to B-ALCL. ALCL Hodgkin's-like.
Classic HD.
For neoplastic cells or reactive cells (Fig IF) . HD cases with perforin-positive tumor cells and additional 24 unselected cases were subjected to immunostaining for granzyme B. Expression of this molecule was found in Hodgkin and ReedStemberg cells in four cases (Tables 2 and 3 ). Expression of both perforin transcripts and granzyme B was variable, ranging from a few (-1%) to a considerable number (30%) of neoplastic cells. The results of additional phenotypic analysis for T-cell antigens, CD56, and LMP expression are summarized in Table 3 . Two of 23 HD cases with EBVpositive tumor cells and three of 29 EBV-negative HD cases contained cytotoxic molecules in the tumor cells. Both CD8' peripheral Tcell lymphomas (one nodal case and one extranodal angiocentric case) demonstrated expression of both perforin transcripts and granzyme B molecules in the majority of neoplastic cells, whereas expression of these molecules was limited to reactive cells in seven CD8-cases ( Table 2) .
Reactive Zymph nodes. Simultaneous immunohistology for CD30 and ISH for perforin transcripts showed that few Peripheral T-cell lymphomas.
(< 1 %) of all the CD30+ cells contained perforin transcripts (not shown).
DISCUSSION
ALCLs have been identified as a distinct group of largecell lymphomas.' Among T-or null-ALCLs, two clinical subentities have emerged: a primary systemic form and a primary cutaneous Despite this progress, the precise cellular origin of ALCL, as well as the relationship of immunophenotypic and clinical ALCL subforms to each other and to HD, remained unclear.2 The molecular characterization of pathways resulting in apoptosis has led to the identification of a series of cytotoxic molecules, including perforin and granzyme B. The aim of the present study was to clarify some of the above-mentioned issues by investigation of the presence of cytotoxic molecules. For this purpose, ISH and immunohistology were used for detection of perforin and granzyme B, respectively. In T-or null-ALCL, perforin transcripts were found in the majority of neoplastic cells in 22 of 25 cases, and granzyme B was detectable in the tumor cells of 19 of 21 cases. Cytotoxic molecules were not detectable in the tumor cells of B-ALCL or CD8-peripheral Tcell lymphoma and the vast majority of classic HD cases, whereas they were found in CD8+ T-cell lymphomas. Most cases of T-or null-ALCL, but not B-ALCL, contained a clonally rearranged T-cell receptor &chain gene.
The justification for the use of cytotoxic molecules as lineage markers lies within their largely restricted expression in cytotoxic cell^.^.".^^ One possible exception appears to be activated CD34+ hematopoetic stem cells, which may contain some of these m0lecules.2~ However, these cells are not likely to represent the cellular origin of ALCL, since they do not display T-cell antigens, activation antigens, and rearranged T-cell receptor genes as ALCL frequently does2
Thus, as derived from our results, cytotoxic T cells and natural killer cells remain the potential candidates for the cellular origin of ALCL. Because the most valid criterion for the distinction between these lines is the absence of rearranged T-cell receptor genes in natural killer cells,% PCR analysis for the presence of rearranged T-cell receptor genes was performed in our ALCL cases. The demonstration of clonally rearranged T-cell receptor 0 genes in the vast majority of T-or null-ALCL cases, which is in agreement with earlier Southern blot therefore indicates a derivation from cytotoxic T cells rather than natural killer cells, a notion further supported by the demonstration of CD8 in nine of 21 ALCL cases and the absence of CD56 in 13 of 13 ALCL cases. The demonstration of a CD4+ phenotype is not contradictory with this concept, since CD4+ lymphocytes may demonstrate cytotoxic activity'," and some CD4+ peripheral T-cell lymphomas have been shown to contain granzyme B.26 CD30' extrafollicular blasts containing perforin transcripts were occasionally found in reactive lymph nodes, and these cells, which may represent activated cytotoxic cells, could be the cellular origin of T-or null-ALCL.
Our study showed expression of cytotoxic molecules and rearranged T-cell receptor genes in both null-and T-ALCL. These data indicate that null-ALCL and T-ALCL are members of the same distinct lymphoma entity, a notion also supported by the finding of the t(2; 5) translocation in both ALCL types.27 The absence of expression of other T-cell antigens in the neoplastic cells of null-ALCL would then represent a loss of these antigens, such as commonly observed in peripheral T-cell lymphomas and particularly in large atypical cell types and lymphomas.' B-ALCL appears to be different from these lymphomas with respect to all of the above-mentioned features,27 as well as with respect to the expression of other lineage-associated antigens' such as CD3 and CD20, and is therefore likely to represent a different lymphoma entity. Our data on the occurrence of granzyme B in ALCL do not fully correspond to those reported in a previous wherein granzyme B was found in only four of 25 ALCL cases. Although the reason for this discrepancy is not clear, one apparent distinction is the different evaluation criteria. De Bruin et alZ6 considered a case positive only when greater than 50% of neoplastic cells contained granzyme B, whereas we considered a case positive when there was unequivocal staining of neoplastic cells irrespective of their number. The justification for these different criteria is that in peripheral T-cell lymphoma, differentiation between reactive, possibly cytotoxic T cells and neoplastic cells may be exceedingly difficult, and thus quantity (>50% of the cellular infiltrate being labeled) appears to be the best criterion for scoring a case positive. In contrast, in ALCL and similarly in HD, the tumor cells have a distinct morphology, and thus even a small number of labeled tumor cells may be recognized with confidence. It is also noteworthy that De Bruin et a1 used the same criteria as used in this study for evaluation of HD." The specificity of our immunohistologic staining and the interpretation of the staining results is corroborated by the ISH experiments, which showed expression of perforin transcripts in the vast majority of tumor cells, even in cases with granzyme B immunoreactivity confined to a few neoplastic cells.
In contradistinction to ALCL, HD less frequently showed an expression of cytotoxic molecules in neoplastic cells. These data are largely in agreement with those obtained by Oudejans et a1; ' who found expression of granzyme B in approximately 20% (1 1 of 58) of HD cases. As in the case of ALCL, our results, which showed expression of granzyme B and perforin in Hodgkin and Reed-Stemberg cells in a few HD cases, suggest that these cells may originate in a minor group of cases from natural killer cells or cytotoxic T cells. Cytotoxic molecules were only found in one of five cases of ALCL Hodgkin's-like. In view of the expression pattern of these molecules in null-or T-ALCL and HD, this may indicate that most cases of ALCL Hodgkin's-like are more closely related to HD than to ALCL.
In conclusion, our data suggest that T-and null-ALCLs are members of the same distinct lymphoma entity, and are derived in the majority of cases from activated cytotoxic T cells. B-ALCL is clearly different from these lymphomas both with respect to phenotype, with a lack of expression of T-cell antigens and cytotoxic molecules, and with respect to genetic lesions, with an absence of the t(2;5) translocation. Although they support the notion that HD is a lymphoid neoplasm, HD cases with Hodgkin and Reed-Sternberg cells derived from cytotoxic T cells are a rare event.
